REVIEW

Development of comprehensive disease assessment in systemic vasculitis

Oliver Flossmann, Paul Bacon, Kirsten de Groot, David Jayne, Niels Rasmussen, Philip Seo, Kerstin Westman, Raashid Luqmani

Ann Rheum Dis 2007;66:283–292. doi: 10.1136/ard.2005.051078

The systemic vasculitides are multisystem disorders with considerable mortality and morbidity and frequent relapses. In the absence of reliable serological markers, accurate clinical tools are required to assess disease activity and damage for treatment decisions, and for the performance of clinical trials. This article reviews and summarises the development and use of disease assessment tools for determining activity and damage in systemic vasculitis and reports ongoing initiatives for further development of disease assessment tools. A literature search was conducted using PubMed and reference lists for vasculitis, assessment, clinical trials, outcome and prognosis. The findings indicate that comprehensive disease assessment in vasculitis requires documentation of disease activity, chronic irreversible damage and impairment of function.

extension of this would be to stratify treatment according to probable outcome.

DISEASE ASSESSMENT MEASURES

Several groups have independently approached the problem of multisystem clinical evaluation in systemic vasculitis. A comparison of the underlying dataset of different disease assessment tools in current use suggests that by consensus, clinicians mostly agree on clinical symptoms and signs that represent disease activity in vasculitis treatment decisions (table 1).

An alternative view of clinical evaluation of patients with systemic vasculitis is that each disease should have its own unique dataset. However, there is considerable evidence that patients with different forms of primary small-vessel or medium-vessel vasculitis share common features.^{11–12} Intuitively, the common generic dataset should be used with the understanding that not all aspects of the dataset are required in every patient. Indeed, the major European Vasculitis Study (EUVAS) Group trials have grouped together the antineutrophil cytoplasmic antibody (ANCA)-related small-vessel vasculitides for the purposes of treatment and analysis.¹³ Further, there are a large number of patients in whom a specific diagnostic label cannot be applied and yet who clearly fulfil a diagnosis of vasculitis.^{14–15}

Early measures

Early development of disease activity measures such as the Groningen Index¹⁶ for Wegener's granulomatosis were based on the clinical features of disease with additional laboratory support. The dependence on biopsy findings for evidence of active vasculitis, which is entirely appropriate at diagnosis, made this an impractical tool for use in the follow-up of patients. The Baltimore Group developed a vasculitis activity index, which consists of a rating scale of disease in several organ systems.¹⁷ This introduces a possible observer bias and is not widely used.

In several complex rheumatic diseases, measurement of disease morbidity is becoming increasingly important. Patients with rheumatoid arthritis, lupus and vasculitis are expected to live for many years, but they also have frequent episodes of relapse, accumulation of damage and drug toxicity.^{1–3} In this context, indices of clinical disease assessment have become necessary because of the failure of serological markers to provide accurate information to stage patients for appropriate treatments. In rheumatoid arthritis, the widespread use of the Disease Assessment Score⁴ provides an international comparison among patients as a basis for clinical trials.^{5–6} In systemic lupus erythematosus, the British Isles Lupus Assessment Group index and other indices have been developed to measure disease activity.⁷ Disease activity in lupus has been separated from damage (non-healing scars) using the Systemic Lupus International Cooperating Clinics Index.⁸ In vasculitis, the Birmingham Vasculitis Activity Score (BVAS)⁹ and other similar scores have been applied to assess disease activity, whereas the Vasculitis Damage Index (VDI)¹⁰ provides information on disease damage.

The objective of all scores is to provide a detailed description of the clinical status of patients with chronic rheumatic diseases. The information gathered during clinical evaluation of patients with vasculitis can be transformed into a variety of quantitative scores that may provide a justification for treatment decisions; the same information may be used to give an indication of prognosis, and an

See end of article for authors' affiliations

Correspondence to:
Dr R Luqmani, Department
of Rheumatology, Nuffield
Orthopaedic Centre,
Windmill Road, Oxford
OX3 7LD, UK;
raashid.luqmani@noc.
anglo.nhs.uk

Accepted 1 May 2006
Published Online First
25 May 2006

Abbreviations: ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis; DEI, Disease Extent Index; EUVAS, European Vasculitis Study Group; FFS, Five Factor Score; ITU, intensive treatment unit; OMERACT, Outcome Measures for Arthritis Clinical Trials; VDI, Vasculitis Damage Index

Table 1 Assessment tools and websites

Tools	Websites
Original BVAS	http://www.ndos.ox.ac.uk
BVAS 1/2	http://www.ndos.ox.ac.uk
BVAS/WG	http://www.clevelandclinic.org/arthritis/vasculitis/glossary.htm
BVAS 2003	http://www.ndos.ox.ac.uk
VDI	http://www.ndos.ox.ac.uk
DEI	http://rarediseasesnetwork.epi.usf.edu/vcrc/investigators/omi.htm
Five Factor Score	http://rarediseasesnetwork.epi.usf.edu/vcrc/investigators/omi.htm

BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis; DEI, Disease Extent Index; VDI, Vasculitis Damage Index.

THE BIRMINGHAM VASCULITIS ACTIVITY SCORE

The current standard assessment tool for scoring disease activity in systemic vasculitis is the BVAS.⁹ The important principle that applies to all assessment measures is to ensure that an abnormality is recorded only when it is attributed to active vasculitis. The reason for this important distinction is that many of the features that occur in vasculitis could equally occur as a result of other causes. For example, the presence of haematuria could be due to vasculitis, urinary infection or cyclophosphamide bladder toxicity.

After initial validation in patients with vasculitis in a variety of disease states, the first version of BVAS was published in 1994.⁹ Since then, the list of clinical features has been revised for use in European vasculitis studies by the EUVAS by omitting four of the initial items that were thought to occur only rarely and by adding seven new items including features available after specialist (eg, ophthalmology) opinion and tests.¹⁸ Altogether, 66 clinical features are included. These items are grouped into nine different organ systems. Each item is given an arbitrary numerical value according to its perceived clinical relevance. For example, nasal crusting carries a value of 2 whereas haematuria has a value of 6. The different organ systems are also weighted according to clinical relevance by applying maximal scores for each system. For example, ENT has a maximal score of 6, whereas the renal system has 12. In the latest version of BVAS called BVAS 2003, which is currently undergoing validation, the list of the clinical features has been further revised (fig 1). Four new items have been added, four items of low specificity for vasculitis have been omitted and items that are due to the same underlying pathological process have been grouped together. Figures 2 and 3 give details of the glossary and scoring in the BVAS 2003.

Without specific training in the use of BVAS, even doctors who were experienced at managing vasculitis struggled to use the score as originally intended. The result was wide interobserver variation, which improved dramatically after group discussion and a better appreciation of the nature of the score. Areas of greatest contention were of two varieties. Firstly, there was a tendency to overscore patients who had established fixed lesions such as stroke or chronic kidney disease, which appeared as items on the BVAS list but did not represent new or worsening disease or even grumbling disease. The second area of controversy was related to the distinction between active vasculitis and infection, especially in the upper airways. As a result of some of these discussions, a glossary of terms was developed for the BVAS and published along with the new version of the assessment tool,¹⁹ emphasising the requirement to score an item only if it is due to active vasculitis based on clinical judgement.

In the next phase of development of the BVAS, the International Network for Study of Systemic Vasculitis

reviewed and revised the BVAS for use in a clinical trial of patients with Wegener's granulomatosis. This tool is called the Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG).²⁰ The focus of the trial was on Wegener's granulomatosis, and features that were less common or absent in Wegener's granulomatosis were therefore omitted. Items due to similar pathological processes were merged and new items more specific for Wegener's granulomatosis (eg, endobronchial disease) were introduced. The arbitrary weighting in the original BVAS was reviewed and changed, with a further arbitrary weighting assigning one point to any item judged to be of a minor nature and three points to any item of a major nature. A major item was one that would normally require the clinician to introduce aggressive treatment such as cyclophosphamide, whereas a minor item required an increased dose of steroids or the introduction of a less toxic immunosuppressant such as methotrexate. The BVAS/WG was supplemented by a visual analogue scale of physician's global assessment of disease activity and an opportunity to assign patients to specific disease states of remission, minor flare or major flare. The BVAS/WG was validated and introduced for the purposes of that particular clinical trial, and has the advantage of greater disease specificity over the original BVAS in patients with Wegener's granulomatosis; however, it has not been validated outside this specific disease, and therefore cannot be recommended for general use.²⁰

Grumbling disease

An apparent problem in the initial use of the BVAS was how to record low grade or "grumbling" disease activity. Some patients, although clearly improving on treatment, have ongoing low-grade manifestations of vasculitis, which are usually not thought to warrant an intensification of treatment. The original score included only clinical features that were either new or worse in the month before the assessment. For this reason, a second column, labelled BVAS2, was added when the original score was revised by the EUVAS Group (in addition to the first column that is used to record the presence of new or worsening features of vasculitis).²¹ However, the addition of the BVAS2 led to confusion among researchers. It was often impossible to distinguish between ongoing symptoms due to active vasculitis and symptoms due to scarring without an underlying active vasculitic process. For this reason, the separate BVAS2 column has been omitted from the BVAS 2003 version. In this version, there is the opportunity to record "persistent only disease" if all positive items are thought to be due to active but not new or worse disease activity. This certainly does not provide a final answer for this intractable problem. However, there is a limit on how much complexity can be introduced without the tool becoming too clumsy to be useful in practice.

Clinical trials

The BVAS has been used in >10 published therapeutic trials on vasculitis by various groups over the past 5 years²²⁻³¹ (table 2). It has become the standard disease activity measure in clinical trials on patients with various forms of vasculitis and for the development of serological markers of disease activity, and it has stood the test of time.

In comparatively rare diseases such as the vasculitides, it is highly desirable that a single standard structured clinical disease activity measure is used, in order to allow comparisons between different studies.

The BVAS has also been shown to have prognostic value, at least in short- to medium-term mortality, which makes clinical sense. The relationship between initial disease activity and subsequent risk of mortality is probably going to become less clear over time. Damage measures are possibly better at

VASCULITIS ACTIVITY SCORE 2003			
☐ Tick box only if abnormality represents active disease (use the Vasculitis Damage Index, VDI to score items of damage). If there are no abnormalities in a system, please tick the "None" box		☐ If all the abnormalities recorded represent smouldering/low grade/grumbling disease, and there are no new/worse features, please remember to tick the box at the bottom right corner	
	None ☐	Active disease ☐	
1. General Myalgia Arthralgia or arthritis Fever $\geq 38.0^{\circ}\text{C}$ Weight loss ≥ 2 kg		6. Cardiovascular Loss of pulses Valvular heart disease Pericarditis Ischaemic cardiac pain Cardiomyopathy Congestive cardiac failure	
2. Cutaneous Infarct Purpura Ulcer Gangrene Other skin vasculitis		7. Abdominal Peritonitis Bloody diarrhoea Ischaemic abdominal pain	
3. Mucous membranes/eyes Mouth ulcers/granulomata Genital ulcers Adnexal inflammation Significant proptosis Red eye (Epi)scleritis Red eye conjunctivitis/blepharitis/keratitis Blurred vision Sudden visual loss Uveitis Retinal vasculitis/retinal vessel thrombosis/retinal exudates/retinal haemorrhages		8. Renal Hypertension Proteinuria $> 1+$ Haematuria ≥ 10 rbc/hpf Creatinine 125-249 $\mu\text{mol/l}$ Creatinine 250-499 $\mu\text{mol/l}$ Creatinine ≥ 500 $\mu\text{mol/l}$ Rise in creatinine $> 30\%$ or creatinine clearance fall $> 25\%$	
4. ENT Bloody nasal discharge/nasal crusts/ulcers and/or granulomata Paranasal sinus involvement Subglottic stenosis Conductive hearing loss Sensorineural hearing loss		9. Nervous system Headache Meningitis Organic confusion Seizures (not hypertensive) Stroke Cord lesion Cranial nerve palsy Sensory peripheral neuropathy Motor mononeuritis multiplex	
5. Chest Wheeze Nodules or cavities Pleural effusion/pleurisy Infiltrate Endobronchial involvement Massive haemoptysis/alveolar haemorrhage Respiratory failure		10. Other 	
Persistent disease only: Tick here if all the above abnormalities are due to low grade grumbling disease and not due to new/worse disease ☐			

Figure 1 (A)Vasculitis activity score 2003.

predicting long-term outcome. In one cross-sectional study of 213 consecutive patients, mortality occurred only in patients with an initial BVAS > 8 .⁹ In a retrospective series of 278

patients, BVAS was markedly higher in a patient who subsequently died than in survivors.³⁴ Although no separate analysis was performed, it seemed that the greatest divergence

Glossary and scoring for BVAS 2003. GENERAL RULE: disease features are scored only when they are due to active vasculitis, after excluding other causes (e.g. infection, hypertension, etc.). If the feature is due to active disease, it is scored in the boxes. It is essential to apply these principles to each item below. Scores have been weighted according to the severity which each symptom or sign is thought to represent. Tick "Persistent Disease" box if all the abnormalities are due to active (but not new or worse) vasculitis. If any of the abnormalities are due to new/worse disease, DO NOT tick the "Persistent Disease" box. For some features, further information (from specialist opinion or further tests) is required if abnormality is newly present or worse. Remember that in most instances, you will be able to complete the whole record when you see the patient. However, you may need further information before entering some items. Please leave these items blank, until the information is available, and then fill them in. For example, if the patient has new onset of stridor, you would usually ask an ENT colleague to investigate this further to determine whether or not it is due to active Wegener's granulomatosis.			
		BVAS persistent	BVAS new/worse
1. General	Maximum scores	2	3
Myalgia	Pain in the muscles	1	1
Arthralgia or arthritis	Pain in the joints or joint inflammation	1	1
Fever $\geq 38.0^{\circ}\text{C}$	Documented oral/axillary temperature elevation. Rectal temps are 0.5°C higher	2	2
Weight loss	At least 2 kg loss of body weight (not fluid) having occurred since last assessment or in the 4 weeks not as a consequence of dieting	2	2
2. Cutaneous	Maximum scores	3	6
Infarct	Area of tissue necrosis or splinter haemorrhages	1	2
Purpura	Petechiae (small red spots), palpable purpura, or ecchymoses (large plaques) in skin or oozing (in the absence of trauma) in the mucous membranes.	1	2
Ulcer	Open sore in a skin surface.	1	4
Gangrene	Extensive tissue necrosis (e.g. digit)	2	6
Other skin vasculitis	Livedo reticularis, subcutaneous nodules, erythema nodosum, etc	1	2
3. Mucous membranes/eyes	Maximum scores	3	6
Mouth ulcers/granulomata	Aphthous stomatitis, deep ulcers and/or "strawberry" gingival hyperplasia, excluding lupus erythematosus, and infection	1	2
Genital ulcers	Ulcers localised in the genitalia or perineum, excluding infections.	1	1
Adnexal inflammation	Salivary (diffuse, tender swelling unrelated to meals) or lacrimal gland inflammation. Exclude other causes (infection). Specialist opinion preferably required.	2	4
Significant proptosis	Protrusion of the eyeball due to significant amounts of inflammatory in the orbit; if unilateral, there should be a difference of 2 mm between one eye and the other. This may be associated with diplopia due to infiltration of extra-ocular muscles. Developing myopia (measured on best visual acuity, see later) can also be a manifestation of proptosis	2	4
Red eye (Epi)scleritis	Inflammation of the sclerae (specialist opinion usually required). Can be heralded by photophobia.	1	2
Red eye conjunctivitis	Inflammation of the conjunctivae (exclude infectious causes and excluding uveitis as cause of red eye, also exclude conjunctivitis sicca which should not be scored as this is not a feature of active vasculitis); (specialist opinion not usually required).	1	1
Blepharitis	Inflammation of eyelids. Exclude other causes (trauma, infection). Usually no specialist opinion is required		
Keratitis	Inflammation of central or peripheral cornea as evaluated by specialist		
Blurred vision	Altered measurement of best visual acuity from previous or baseline, requiring specialist opinion for further evaluation.	2	3
Sudden visual loss	Sudden loss of vision requiring ophthalmological assessment.		6
Uveitis	Inflammation of the uvea (iris, ciliary body, choroid) confirmed by ophthalmologist.	2	6
Retinal vasculitis	Retinal vessel sheathing on examination by specialist or confirmed by retinal fluorescein angiography	2	6
Retinal vessel thrombosis	Arterial or venous retinal blood vessel occlusion		
Retinal exudates	Any area of soft retinal exudates (exclude hard exudates) seen on ophthalmoscopic examination.		
Retinal haemorrhages	Any area of retinal haemorrhage seen on ophthalmoscopic examination.		
4. ENT	Maximum scores	3	6
Bloody nasal discharge/nasal crusts/ulcers and/or granulomata	Bloody, mucopurulent, nasal secretion, light or dark brown crusts frequently obstructing the nose, nasal ulcers and/or granulomatous lesions observed by rhinoscopy	3	6
Paranasal sinus involvement	Tenderness or pain over paranasal sinuses usually with pathologic imaging (CT, MR, x-ray, ultrasound)	1	2
Subglottic stenosis	Stridor and hoarseness due to inflammation and narrowing of the subglottic area observed by laryngoscopy	3	6
Conductive hearing loss	Hearing loss due to middle ear involvement confirmed by otoscopy and/or tuning fork examination and/or audiometry	1	3
Sensorineural hearing loss	Hearing loss due to auditory nerve or cochlear damage confirmed by audiometry	2	6

Figure 2 Glossary and scoring for the BVAS 2003 (general, cutaneous, mucous membranes/eyes and ENT). CT, computed tomography; MR, magnetic resonance.

in the Kaplan–Meier survival curves was in the initial 18 months. In another retrospective analysis of 26 patients in the intensive treatment unit (ITU), the BVAS at the time of

admission to the ITU was predictive of survival at the end of follow-up after a mean of 31.4 months but not predictive of survival in the ITU.³⁵ However, other retrospective studies did

Glossary and scoring for BVAS 2003 continued			
		BVAS persistent	BVAS new/worse
5. Chest	Maximum scores	3	6
Wheeze	Wheeze on clinical examination	1	2
Nodules or cavities	New lesions, detected by CXR		3
Pleural effusion/pleurisy	Pleural pain and/or friction rub on clinical assessment or new onset of radiologically confirmed pleural effusion. Other causes (e.g. infection, malignancy) should be excluded	2	4
Infiltrate	Detected by CXR or CT scan. Other causes (infection) should be excluded	2	4
Endobronchial involvement	Endobronchial pseudotumor or ulcerative lesions. Other causes such as infection or malignancy should be excluded. NB: smooth stenotic lesions to be included in VDI; subglottic lesions to be recorded in the ENT section.	2	4
Massive haemoptysis/alveolar haemorrhage	Major pulmonary bleeding, with shifting pulmonary infiltrates; other causes of bleeding should be excluded if possible	4	6
Respiratory failure	Dyspnoea which is sufficiently severe as to require artificial ventilation	4	6
6. Cardiovascular	Maximum scores	3	6
Loss of pulses	Loss of pulses in any vessel detected clinically; this may include loss of pulses leading to threatened loss of limb	1	4
Valvular heart disease	Significant valve abnormalities in the aortic mitral or pulmonary valves detected clinically or echocardiographically.	2	4
Pericarditis	Pericardial pain and/or friction rub on clinical assessment.	1	3
Ischaemic cardiac pain	Typical clinical history of cardiac pain leading to myocardial infarction or angina. Consider the possibility of more common causes (eg atherosclerosis)	2	4
Cardiomyopathy	Significant impairment of cardiac function due to poor ventricular wall motion confirmed on echocardiography	3	6
Congestive cardiac failure	Heart failure by history or clinical examination	3	6
7. Abdominal	Maximum scores	4	9
Peritonism	Acute abdominal pain with peritonism/peritonitis due to perforation/infarction of small bowel, appendix or gallbladder etc., or acute pancreatitis confirmed by radiology/surgery/elevated amylase	3	9
Bloody diarrhoea	Of recent onset; inflammatory bowel disease and infectious causes excluded.	3	9
Ischaemic abdominal pain	Severe abdominal pain with typical features of ischaemia confirmed by imaging or at surgery, with typical appearances of aneurysms or abnormal vasculature characteristic of vasculitis.	2	6
8. Renal	Maximum scores	6	12
Hypertension	Diastolic BP >95, accelerated or not, with or without retinal changes.	1	4
Proteinuria	>1+ on urinalysis; >0.2 g/24 hours Infection should be excluded.	2	4
Haematuria	10 or more RBC per hpf (high power field), excluding urinary infection and urinary lithiasis (stone)	3	6
Creatinine 125–249	Serum creatinine values 125–249 µmol/l at first assessment only.	2	4
Creatinine 250–499	Serum creatinine values 250–499 µmol/l at first assessment only.	3	6
Creatinine ≥500	Serum creatinine values 500 µmol/l or greater at first assessment only.	4	8
Rise in creatinine >30% or creatinine clearance fall >25%	Significant deterioration in renal function attributable to active vasculitis.		6
9. Nervous system	Maximum scores	6	9
Headache	New, unaccustomed and persistent headache	1	1
Meningitis	Severe headache with neck stiffness ascribed to inflammatory meningitis after excluding infection/bleeding	1	3
Organic confusion	Impaired orientation, memory or other intellectual function in the absence of metabolic, psychiatric, pharmacological or toxic causes.	1	3
Seizures (not hypertensive)	Paroxysmal electrical discharges in the brain and producing characteristic physical changes including tonic and clonic movements and certain behavioural changes.	3	9
Stroke	Cerebrovascular accident resulting in focal neurological signs such as paresis, weakness, etc. A stroke due to other causes (eg atherosclerosis) should be considered and appropriate neurological advice is recommended	3	9
Cord lesion	Transverse myelitis with lower extremity weakness or sensory loss (usually with a detectable sensory level) with loss of sphincter control (rectal and urinary bladder).	3	9
Cranial nerve palsy	Facial nerve palsy, recurrent nerve palsy, oculomotor nerve palsy etc. excluding sensorineural hearing loss and ophthalmic symptoms due to inflammation	3	6
Sensory peripheral neuropathy	Sensory neuropathy resulting in glove and/or stocking distribution of sensory loss. Other causes should be excluded (e.g. idiopathic, metabolic, vitamin deficiencies, infectious, toxic, hereditary).	3	6
Motor mononeuritis/multiplex	Simultaneous neuritis of single or many peripheral nerves, only scored if motor involvement. Other causes should be excluded (diabetes, sarcoidosis, carcinoma, amyloidosis).	3	9
10. OTHER	Other feature of active vasculitis-please describe		

Figure 3 Glossary and scoring for the BVAS 2003 (chest, cardiovascular, abdominal, renal, nervous system, other). CT, computed tomography; MR, magnetic resonance; RBC, red blood cells; VDI, Vasculitis Damage Index.

Table 2 Use of Birmingham Vasculitis Activity Score and Birmingham Vasculitis Activity Score for Wegener's granulomatosis in clinical trials

Trial	Details	Intervention	Outcome	BVAS at entry	Disease assessment scores used
Keogh <i>et al</i> , ³² 2006	Prospective, open-label, 10 WG	Rituximab for refractory vasculitis	CR at 3 months 100%	Median 6	BVAS/WG, SF-36
WGET, ³³ 2005	Double-blind RCT, 180 WG	Standard treatment+etanercept v placebo for remission maintenance	No major difference in sustained remission rates (69.7% v 75.3%)	Mean 6.5 and 7.5	BVAS/WG, VDI, SF-36
De Groot <i>et al</i> , ²² 2005	RCT, 100 new onset AASV	MTX v CYC for remission induction	Remission 6 months, MTX 89.8%, CYC 93.5%	Median 1.5	BVAS 1+2, DEI, VDI
Benenson <i>et al</i> , ²³ 2005	Open-label, 4 WG, 2 LN	High dose intravenous Aza in refractory WG or LN	2 CR, 2 PR (LN), 2 no response	Range 2–14	BVAS, SLEDAI
Joy <i>et al</i> , ³¹ 2005	Prospective, open-label, 12 AASV	MMF for relapsing or persistent disease	Reduction in BVAS at 24 and 52 weeks	Mean 9.1	BVAS 1+2
Booth <i>et al</i> , ²⁷ 2004	Prospective, open-label, 32 AASV	Addition of infliximab for remission induction in new and persistent disease	Remission 88%	Mean 12.3	BVAS 1+2
Metzler <i>et al</i> , ²⁸ 2004	Prospective, open-label, 20 WG	Leffunomide for remission maintenance	1 major and 8 minor relapses; median follow-up 1.75 years	Median 0	DEI, BVAS, SF-36
Danieli <i>et al</i> , ²⁴ 2004	Non-randomised, prospective, historic controls, 18 CSS	Addition of iv Ig+PP v standard treatment alone in new CSS	Remission 12 months, iv Ig 100%, control 44%	Range 13–31	BVAS, FFS, Rankin score, SNVDI
Jayne <i>et al</i> , ²⁵ 2003	RCT, 155 new-onset AASV	Aza v CYC for remission maintenance	Relapse 18 months, Aza 15.5%, CYC 13.7%	Mean 18	BVAS 1+2, DEI, VDI, SF-36
Birck <i>et al</i> , ³⁰ 2003	Prospective, open-label, 19 WG, 1 MPA	DSG in refractory disease	6 CR and 8 PR after 6 months	Range 3–25	BVAS, VDI, SF-36
Bartolucci <i>et al</i> , ²⁹ 2002	Prospective, open-label, 7 WG, 2 RV, 1 Cryo	Infliximab+CS for refractory vasculitis	5 CR and 5 PR after 6 months	Mean 9.1	BVAS
Stone <i>et al</i> , ²⁰ 2001	Prospective, open-label, 20 WG	Standard treatment+etanercept for relapsing and persistent disease	80% achieved BVAS/WG at some point	Mean BVAS/WG 3.6	BVAS/WG
Jayne <i>et al</i> , ²⁶ 2000	Double-blind, placebo-controlled, 34 AASV	Standard treatment+iv Ig v placebo for persistent disease	Therapeutic response at 3 months, iv Ig 82.4%; placebo 35.3%	Mean 6.1 and 5.4	BVAS

AASV, antineutrophil cytoplasmic antibody-associated systemic vasculitis; Aza, azathioprine; BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis; CR, complete remission; Cryo, cryoglobulinaemia; CS, corticosteroids; CSS, Churg–Strauss syndrome; CYC, cyclophosphamide; DEI, Disease Extent Index; DSG, deoxyspergualin; FFS, Five Factor score; iv Ig, intravenous immunoglobulin; LN, lupus nephritis; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; PP, plasmapheresis; PR, partial remission; RCT, randomised controlled trial; RV, rheumatoid arthritis vasculitis; SF-36, Short Form 36; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SNVDI, Systemic Necrotising Vasculitis Damage Index; VDI, Vasculitis Damage Index; WG, Wegener's granulomatosis.

not confirm a prognostic value of baseline BVAS for survival after a mean follow-up of 56.5 and 26 months in 56 and 99 patients with vasculitis, respectively.^{36–37} A large prospective study is under way to resolve this issue.

Future development

Evolution of BVAS is necessary, just as in any clinical tool where there is no gold standard. The cycle of design followed by implementation, evaluation, redesign and further testing is constant, which means that we will never have a perfect instrument, but each cycle will lead to data-driven improvement. These principles are applied to many of the clinical measures tested by the Outcome Measures for Arthritis Clinical Trials (OMERACT) Consensus Group.³⁸ The next phase of development for the BVAS is to draw together some of the lessons from the previous versions and improve the instrument. Current discussions in the OMERACT Group³⁹ are designed to resolve these problems.

OTHER DISEASE MEASURES

The Disease Extent Index (DEI) scores the number of organ systems affected, is unweighted and correlates with the BVAS.⁴⁰ It complements the BVAS in that a combination of both scores shows whether, for example, a high BVAS is due to severe manifestation in only one organ system or is due to multisystem disease.

The Five Factor Score (FFS)⁴¹ was developed using the prognostic value on outcome of different clinical features in a

large number of patients with polyarteritis nodosa and Churg–Strauss syndrome. Five relevant risk factors at presentation for poor prognosis were derived from the data (renal impairment, proteinuria and involvement of the cardiovascular, gastrointestinal and central nervous systems). The FFS provides a useful prognostic index in these two diseases and may be of value for prognosis of other diseases, but it has not been widely tested in patients with Wegener's granulomatosis or microscopic polyangiitis. Its effectiveness in distinguishing outcome has led investigators to use the FFS score at the onset to determine the treatment strategy chosen. The FFS and the DEI can be derived from the dataset recorded for the BVAS.

A recent comparison of the BVAS, BVAS/WG, BVAS 2003 and DEI showed a good correlation among these different indices.⁴² As all these tools use more or less the same disease features to record activity, it was suggested that differences in the arbitrary weighting of individual items was not of major importance. This topic is being actively investigated by the OMERACT Group.

DEFINING DISEASE STATUS

Definitions of disease status are an important requirement to measure the effectiveness of different treatments in clinical trials. The loose clinical definitions of remission, relapse and partial remission used in previous studies are no longer satisfactory. These definitions need to be more precise and more reproducible so that they can be standardised. The EUVAS

Table 3 Role of disease assessment in systemic vasculitis

Definition	Details	Aim	Available tools
Disease activity	Clinical evaluation	Assist treatment decisions	BVAS BVAS/WG BVAS 2003
Disease extent	Number of involved organ systems	Disease stage	DEI
Prognostic tool	Factors predicting outcome	Appropriate treatment based on prognosis	BVAS Five Factor Score
Outcome assessment	Longitudinal studies on patients with systemic vasculitis	Measure morbidity and mortality	BVAS VDI SF-36
Quality of life	Patient self-assessment	To measure effect of disease and treatment on physical and psychological function	SF-36
Damage	Irreversible damage due to disease activity, drug toxicity or other events	Outcome measure	VDI
Socioeconomic costs	High socioeconomic costs due to disability, hospitalisation and treatment	Evidence-based approach to funding decisions	None at present

BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis; DEI, Disease Extent Index; SF-36, Short Form 36; VDI, Vasculitis Damage Index.

Group has used definitions based on the BVAS in their clinical trials.²¹

International discussions are under way to arrive at agreed definitions of different disease states. Table 3 summarises some of the potential roles of disease assessment tools in systemic vasculitis.

Damage assessment in vasculitis

Damage caused by vasculitis or its treatment may ultimately prove more troublesome than disease activity to the individual patient. Damage is defined as a non-healing scar that is unlikely to respond to immunosuppressive treatment.

Recurrent and persistent disease activity is largely responsible for the damage caused to patients with Wegener's granulomatosis. In the longitudinal Wegener's granulomatosis cohort from the National Institutes of Health, 86% of patients had permanent damage as a consequence of the disease itself and 42% had treatment-related morbidity. This damage included, for example, end-stage renal disease, chronic pulmonary dysfunction, diminished hearing, saddle-nose deformities, blindness and death.⁴³

The VDI is comprised of 64 items of damage (grouped into 11 organ-based systems) defined by a consensus of experts to represent forms of damage occurring in patients with systemic vasculitis (fig 4). As the clinical distinction between activity and damage may be challenging, it is helpful to define damage over time—that is, if a disease manifestation does not respond to appropriate treatment for a certain time, then it should be scored as damage. In the VDI, damage was defined as an irreversible scar lasting >3 months. In the case of defined events, such as gut resection (which is inherently irreversible), scoring was deferred for 3 months to ensure consistency. Items of damage were not weighted. All damage that occurred after the onset of the first symptoms related to the vasculitis was scored, regardless of attribution (to avoid introducing yet another layer of variability). Finally, the VDI was constructed to be a cumulative index; therefore, the VDI score could not decrease over time.⁴⁴

Use of the VDI in patients with vasculitis has shown that the accumulation of damage is bimodal, with an earlier phase due to the vasculitis itself, and a later phase due to treatment. A high BVAS and BVAS/WG at presentation is predictive of a

higher eventual VDI score.^{33–45} The early phase accounts for most damage in patients. Early damage is predictive of mortality. A retrospective study showed that 2 years after diagnosis, a 6-month VDI score >4 was associated with an odds ratio of 12.4 for mortality (95% confidence interval 4.2 to 36.9).⁴⁶ Patients who died had more organ systems involved and a higher total VDI score when measured after 2 years of disease compared with those having non-fatal vasculitis.¹⁰ A baseline VDI score ≥1 was strongly predictive of mortality after a median follow-up of 56.5 months in a retrospective analysis of 56 patients with Wegener's granulomatosis.³⁷

Future developments

The VDI provides the vocabulary and framework to describe the longer-term outcomes in patients with vasculitis. The VDI remains an important outcome for clinical trials; it allows a record to be made of the natural history of treated disease, it enables clinicians to record abnormalities in patients and also assists in the separation of disease activity items that warrant immunosuppression from damage items that do not warrant immunosuppression. The current damage index concepts may need to be revised in the light of use. Irreversibility of all items may not be appropriate, especially if the clinical effects have completely disappeared. The scoring of damage irrespective of attribution could be challenged. It would be helpful to examine the prognostic value of specific items that are either related or not related to disease or its treatment. The index does not involve any specific weighting of items, although subgroups of items may provide subindices. Exploring gradation of damage—for example, the severity of renal impairment rather than the presence or absence of a considerable renal impairment—may be valuable.

TRAINING TO USE DISEASE ASSESSMENT SCORES

Training has become an essential part of any of these assessment packages. Our early experiences within the EUVAS Group showed that even in clinicians who were experienced in managing vasculitis, the consensus between observers for assessing the BVAS and VDI scores was very poor. However, after training there was a dramatic improvement in observer agreement.⁴⁷

VASCULITIS DAMAGE INDEX (VDI)

This is for recording organ damage that has occurred in patients *since the onset of vasculitis*

Patients often have co-morbidity before they develop vasculitis, **which must not be scored**

Record features of active disease using the Birmingham Vasculitis Activity Score (BVAS)

A new patient should **usually have a VDI score of zero**, unless:

(a) they have had vasculitis for more than three months of onset of disease. **and**

(b) the damage has developed or become worse since the onset of vasculitis

	No	Yes		No	Yes
1. Musculoskeletal			Name		
None	☐	☐	Trial Number		
Significant muscle atrophy or weakness		☐	Date		
Deforming/erosive arthritis		☐	Centre		
Osteoporosis/vertebral collapse		☐	7. Peripheral vascular disease		
Avascular necrosis		☐	None	☐	
Osteomyelitis		☐	Absent pulses in one limb		☐
2. Skin/Mucous membranes			2 nd episode of absent pulses in one limb		☐
None	☐		Major vessel stenosis		☐
Alopecia		☐	Claudication > 3 months		☐
Cutaneous ulcers		☐	Minor tissue loss		☐
Mouth ulcers		☐	Major tissue loss		☐
3. Ocular			Subsequent major tissue loss		☐
None	☐		Complicated venous thrombosis		☐
Cataract		☐	8. Gastrointestinal		
Retinal change		☐	None	☐	
Optic atrophy		☐	Gut infarction/resection		☐
Visual impairment/diplopia		☐	Mesenteric insufficiency/pancreatitis		☐
Blindness in one eye		☐	Chronic peritonitis		☐
Blindness in second eye		☐	Oesophageal stricture/surgery		☐
Orbital wall destruction		☐	9. Renal		
4. ENT			None	☐	
None	☐		Estimated/measured GFR ≤ 50%		☐
Hearing loss		☐	Proteinuria ≥ 0.5 g/24 h		☐
Nasal blockage/chronic discharge/crusting		☐	End stage renal disease		☐
Nasal bridge collapse/septal perforation		☐	10. Neuropsychiatric		
Chronic sinusitis/radiological damage		☐	None	☐	
Subglottic stenosis (no surgery)		☐	Cognitive impairment		☐
Subglottic stenosis (with surgery)		☐	Major psychosis		☐
5. Pulmonary			Seizures		☐
None	☐		Cerebrovascular accident		☐
Pulmonary hypertension		☐	2 nd cerebrovascular accident		☐
Pulmonary fibrosis		☐	Cranial nerve lesion		☐
Pulmonary infarction		☐	Peripheral neuropathy		☐
Pleural fibrosis		☐	Transverse myelitis		☐
Chronic asthma		☐	11. Other		
Chronic breathlessness		☐	None	☐	
Impaired lung function		☐	Gonadal failure		☐
6. Cardiovascular			Marrow failure		☐
None	☐		Diabetes		☐
Angina/angioplasty		☐	Chemical cystitis		☐
Myocardial infarction		☐	Malignancy		☐
Subsequent myocardial infarction		☐	Other		☐
Cardiomyopathy		☐			
Valvular disease		☐			
Pericarditis ≥ 3 months or pericardiectomy		☐			
Diastolic BP ≥ 95 or requiring antihypertensive		☐			

Total VDI score. Record the number of positive items (1 point for each). The VDI score can either increase or remain the same over time. Remember to carry forward any previous items of damage.

VDI Modified from Exley AR, Bacon PA, Luqmani et al (1997) Development and initial validation of the VDI, Arthritis Rheum 40 : 371–380

Figure 4 Vasculitis Damage Index.

QUALITY OF LIFE AND SOCIOECONOMIC COSTS

Systemic vasculitis leads to a major impairment in the quality of life^{48–49} and carries a high socioeconomic burden.⁵⁰ The

measures for physical and mental health at diagnosis are markedly impaired in patients compared with the normal population, and this impairment is sustained even after disease

remission is achieved, although function improves considerably with treatment.²⁵

The standard measure of the quality of life in vasculitis is currently the Medical Outcomes Study-Short Form 36 questionnaire.⁵¹ It has been used both in the EUVAS trials and the Wegener's Granulomatosis Etanercept Trial.^{22 25 52} However, because of its generic nature, it might fail to capture items more specific for patients with systemic vasculitis.⁵³

After a disease duration of 4–5 years, about a third of previously employed patients with systemic vasculitis in the US but only 5% of Dutch patients receive a permanent disability allowance, and a much higher proportion report difficulties with normal daily activities, which can lead to financial loss and strain on relationships. Patients with systemic vasculitis require regular medical monitoring because of frequent relapses and need to continue with potentially toxic treatment often for many years. This leads to high utilisation of medical services.^{49 54 55}

Currently, few data are available on the overall socioeconomic effect of the newer medical treatments for vasculitis. Although most of the newer treatments are much more expensive than the current standard treatments, there is the potential of substantial savings if they prove to be more effective and safer in the long-term control of systemic vasculitis.

SUMMARY AND CONCLUSIONS

In vasculitis, there is a need for standardised clinical tools to assess disease activity, damage and function. No universally applicable serological markers are available to assess disease activity or outcome. Clinical tools have been developed to assist in the evaluation of individual patients and help to justify treatment decisions. They can also provide prognostic information. The development of assessment tools in vasculitis has been vital to the success of large international randomised trials which now provide an evidence base for the management of these diseases. The past 15 years have seen the development and wide application of the BVAS and the VDI, which have become the standard measures for disease activity and damage in vasculitis and can be recommended for universal use. The application of these tools requires training, experience and continuous development.

Authors' affiliations

Oliver Flossmann, Raashid Luqmani, Botnar Research Centre, University of Oxford, Oxford, UK

Paul Bacon, Department of Rheumatology, University of Birmingham, Birmingham, UK

Kirsten de Groot, Department of Nephrology, University of Lubeck, Lubeck, Germany

David Jayne, Department of Nephrology, Addenbrooke's Hospital, Cambridge, UK

Niels Rasmussen, Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark

Philip Seo, Vasculitis Center, Johns Hopkins University, Baltimore, Maryland, USA

Kerstin Westman, Department of Nephrology, University of Malmo, Malmo, Sweden

Competing interests: None

REFERENCES

- Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, *et al.* Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. *Arthritis Rheum* 2003;**48**:54–8.
- Gelber AC, Wigley FM. Disease severity as a predictor of outcome in scleroderma. *Lancet* 2002;**359**:277–9.
- Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, *et al.* Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. *Am J Kidney Dis* 2003;**41**:776–84.
- Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;**38**:44–8.
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, *et al.* Infliximab and methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med* 2000;**343**:1594–602.
- Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, *et al.* Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004;**350**:2572–81.
- Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, *et al.* Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). *Q J Med* 1988;**69**:927–37.
- Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. *Br J Rheumatol* 1996;**35**:248–54.
- Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, *et al.* Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. *QJM* 1994;**87**:671–8.
- Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). *Br J Rheumatol* 1998;**37**:57–63.
- Lane SE, Watts RA, Barker TH, Scott DG. Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. *Rheumatology (Oxford)* 2002;**41**:1138–41.
- Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology Classification Criteria in the diagnosis of vasculitis. *Ann Intern Med* 1998;**129**:345–52.
- Jayne D. Update on the European Vasculitis Study Group trials. *Curr Opin Rheumatol* 2001;**13**:48–55.
- Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, *et al.* The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990;**33**:1101–7.
- Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, *et al.* Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994;**37**:187–92.
- Kallenberg CG, Tervaert JW, Stegeman CA. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. *APMIS Suppl* 1990;**19**:37–9.
- Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. *Arthritis Rheum* 1999;**42**:2365–71.
- Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. *Baillieres Clin Rheumatol* 1997;**11**:423–46.
- Luqmani R. Evaluation of vasculitis disease activity in Europe. *Eur J Intern Med* 2001;**12**:401–2.
- Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, *et al.* A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). *Arthritis Rheum* 2001;**44**:912–20.
- Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. *Mayo Clin Proc* 1997;**72**:737–47.
- de Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, *et al.* Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;**52**:2461–9.
- Benenson E, Fries JW, Heilig B, Pollak M, Rubbert A. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. *Clin Rheumatol* 2005;**24**:251–7.
- Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. *Ann Rheum Dis* 2004;**63**:1649–54.
- Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadonienė J, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;**349**:36–44.
- Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, *et al.* Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. *QJM* 2000;**93**:433–9.
- Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, *et al.* Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. *J Am Soc Nephrol* 2004;**15**:717–21.
- Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. *Rheumatology (Oxford)* 2004;**43**:315–20.
- Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, *et al.* Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology (Oxford)* 2002;**41**:1126–32.
- Birk R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, *et al.* 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. *J Am Soc Nephrol* 2003;**14**:440–7.
- Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. *Nephrol Dial Transplant* 2005;**20**:2725–32.

- 32 **Keogh KA**, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med* 2006;**173**:180-7.
- 33 **Seo P**, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). *Arthritis Rheum* 2005;**52**:2168-78.
- 34 **Gayraud M**, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. *Arthritis Rheum* 2001;**44**:666-75.
- 35 **Cruz BA**, Ramanoelina J, Mahr A, Cohen P, Mouthon L, Cohen Y, et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. *Rheumatology (Oxford)* 2003;**42**:1183-8.
- 36 **Lane SE**, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. *QJM* 2005;**98**:97-111.
- 37 **Koldingsnes W**, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. *Rheumatology (Oxford)* 2002;**41**:572-81.
- 38 **Brooks P**, Hochberg M. Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups. *Rheumatology (Oxford)* 2001;**40**:896-906.
- 39 **Merkel PA**, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. *J Rheumatol* 2005;**32**:2488-95.
- 40 **de Groot K**, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. *Clin Nephrol* 2001;**55**:31-8.
- 41 **Guillevin L**, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)* 1996;**75**:17-28.
- 42 **Merkel PA**, Cuthbertson D, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, et al. Comparison of disease activity measures for ANCA-associated vasculitis [abstract]. *Kidney Blood Press Res* 2005;**28**:169-70.
- 43 **Hoffman GS**, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;**116**:488-98.
- 44 **Exley AR**, Bacon PA, Luqmani RA, Kitaz GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. *Arthritis Rheum* 1997;**40**:371-80.
- 45 **Briker F**, Magee CC, Tervaert JW, O'Neill S, Walshe JJ. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. *Clin Nephrol* 1999;**52**:344-51.
- 46 **Exley AR**, Carruthers DM, Luqmani RA, Kitaz GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. *QJM* 1997;**90**:391-9.
- 47 **European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL**. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. *Clin Exp Immunol* 1995;**101**(Suppl 1):29-34.
- 48 **Koutantji M**, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. *Arthritis Rheum* 2003;**49**:826-37.
- 49 **Hoffman GS**, Drucker Y, Cotch MF, Locker GA, Easley K, Kwok K. Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. *Arthritis Rheum* 1998;**41**:2257-62.
- 50 **Cotch MF**. The socioeconomic impact of vasculitis. *Curr Opin Rheumatol* 2000;**12**:20-3.
- 51 **McHorney CA**, Ware JE Jr, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. *Med Care* 1992;**30**(Suppl 1):MS253-65.
- 52 **WGET research group**. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med* 2005;**352**:351-61.
- 53 **Hellmann DB**, Uhlfelder ML, Stone JH, Jenckes MW, Cid MC, Guillevin L, et al. Domains of health-related quality of life important to patients with giant cell arteritis. *Arthritis Rheum* 2003;**49**:819-25.
- 54 **Reinhold-Keller E**, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe HH, et al. Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. *Arthritis Rheum* 2002;**47**:320-5.
- 55 **Boomsma MM**, Bijl M, Stegeman CA, Kallenberg CG, Hoffman GS, Tervaert JW. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. *Arthritis Rheum* 2002;**47**:196-201.